Law360, New York (October 15, 2009) -- Skandia Life Insurance Co. Ltd. has become the latest party to request lead plaintiff status in a consolidated derivative lawsuit accusing Pfizer Inc. executives of harming the company by promoting prescription drugs for unapproved off-label uses.
In a memorandum filed Wednesday in the U.S. District Court for the Southern District of New York, Skandia claims that, as a large institutional investor holding about 2.1 million Pfizer...


